# Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

> **NCT05947383** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sunstone Medical** · enrollment: 56 (estimated)

## Conditions studied

- Cancer
- Major Depressive Disorder

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05947383
- **Lead sponsor:** Sunstone Medical
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-11-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947383, "Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05947383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*